MV Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

MV Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$58	Buy	+1	New	+$55	﹤0.01%	1253
2025 Q3	–	Sell	-8	Closed	-$440	–	1078
2025 Q2	$440	Sell	8 -2	-20%	-$118	﹤0.01%	866
2025 Q1	$707	Sell	10 -60	-86%	-$4.04K	﹤0.01%	788
2024 Q4	$4.6K	Buy	70 +62	+775%	+$4.15K	﹤0.01%	615
2024 Q3	$563	Sell	8 -2	-20%	-$167	﹤0.01%	796
2024 Q2	$824	Buy	10 +5	+100%	+$416	﹤0.01%	705
2024 Q1	$437	Buy	5 +1	+25%	+$90	﹤0.01%	710
2023 Q4	$386	Buy	+4	New	+$354	﹤0.01%	690
2018 Q2	–	Sell	-500	Closed	-$41K	–	356
2018 Q1	$41K	Buy	+500	New	+$42.9K	0.01%	168

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

MV Capital Management's BMRN Position: Q2 2026 in Review

MV Capital Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 1 share worth $58. The stake represents ﹤0.01% of the portfolio and ranks #1253 among its holdings. This is a return to the name: MV Capital Management previously reported a position in BMRN as recently as Q2 2025.

MV Capital Management first reported a position in BMRN in Q1 2018 and has held it in 9 quarters since. The position peaked at $41K in Q1 2018. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

MV Capital Management held 1 share of BioMarin Pharmaceuticals worth $58 as of Q2 2026.
BioMarin Pharmaceuticals was a new MV Capital Management position in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of MV Capital Management's portfolio in Q2 2026, its #1253 holding.
MV Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2018 and has held it in 9 quarters since.
MV Capital Management's BioMarin Pharmaceuticals position peaked at $41K in Q1 2018.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on MV Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.